Introduction
Over the last decade, eosinophilic gastrointestinal diseases (EGIDs) have become increasingly recognized as a clinically relevant and mechanistically baffling group of conditions. Inherent in the diagnosis of these diseases is the finding of 'more than expected' eosinophils in the gastrointestinal tissues; what defines this number is an area of controversy and intrigue. Herein, we summarize clinical studies and identify controversies related to EGIDs.
Gastrointestinal eosinophilia: what is in a number?
Except for the esophagus, all of the remaining gastrointestinal organs contain eosinophils. But, the ambiguity of what constitutes normal and abnormal numbers of eosinophils, contributes to significant confusion revolving around the care of patients with, and pathophysiological mechanisms defining, EGIDs. What are the diagnostic features of these diseases? What are the underlying homing and activation signals that drive the associated eosinophilic inflammation and the gastric, intestinal and/or bowel dysfunction in patients with EGIDs?
To date, the number of eosinophils per high power field (HPF) in a mucosal biopsy remains the gold standard defining histological diagnostic features of EGIDs [1] . Methodologies used to define these thresholds remain troublesome for several reasons including inconsistencies in definitions of what constitutes an eosinophil and the size of a HPF, variability in analysis between pathologists and gastrointestinal/allergy clinicians [2 ], inconsistencies in tissue orientation, limited amount of mucosal surface to assess, and most confusing, what defines normal and abnormal eosinophil numbers within various parts of the intestinal mucosae. Pathologists remain central to the diagnostic process [3] [4] [5] [6] [7] . If one considers EGIDs as a diagnosis, it is worth communicating with the pathologists to understand exactly how and why the specific inflammatory features are reported so that the results can be interpreted in the clinical context from which they were obtained. As these diseases become more common, patients and families are more informed and are beginning to understand how difficult these critical parameters are to define and, thus, may request more information about pathological reports.
Relatively few studies characterize what defines the normal number of eosinophils in the healthy gastrointestinal mucosae. This is a particularly difficult area of investigation because endoscopic sampling of the mucosa would not take place unless a clinical indication existed. One study began to address this issue by counting eosinophils in 'whole tissue sections' from the intestines of otherwise healthy infants and children who died acutely of causes other than gastrointestinal disease (trauma, etc.) [8] . Children ranged in age from 3 weeks to 17 years and a gradient of eosinophil numbers was identified ranging from a few in the stomach to a maximum of 50/HPF in the cecum. Another pediatric study showed virtually the same findings in 'mucosal biopsy samples' [9] . A third study examined histological features of the intestinal 'mucosal biopsy samples' from patients who exhibited a wide range of clinical features and found a similar gradient in the upper gastrointestinal tract [10] . Other studies determined the 'normal' number of eosinophils in the gastric mucosa (15 eos/HPF), colon (approximately <20 eos/HPF) and in the cecum and rectosigmoid [11] [12] [13] . Thus, although a range of numbers characterize the normal gastrointestinal mucosa, a consistently documented trend is the increase in number of eosinophils from the proximal to distal gut. Less certain and not addressed in detail are the local environmental factors that might influence these numbers such as climate, urban/rural setting, diet, and other factors [14] .
Eosinophilic gastrointestinal diseases: clinical features of a heterogeneous group of conditions
Although a number of case reports have described the association of gastrointestinal symptoms with intestinal eosinophilia, the first and earliest comprehensive descriptions were provided by Kaijser [15] and Klein et al. [16] in publications separated by 33 years. In 1937, the single authored German publication by the surgeon Kaijser [15] described a series of patients with various abdominal symptoms and intestinal eosinophilia. In 1970, Klein et al. [16] proposed a novel classification system that separated patients with intestinal eosinophilia into anatomically distinct groupings, that is, mucosal, muscular, or serosal diseases, depending on where the predominant eosinophilia was located. Subsequent to this, a number of investigators have further refined the description of EGIDs as organ-specific diseases, that is, eosinophilic esophagitis (EoE), eosinophilic gastritis, eosinophilic gastroenteritis, and eosinophilic colitis, depending on which part of the gastrointestinal tract is affected by eosinophilic inflammation [17] . Because eosinophils can infiltrate the mucosa as a nonspecific feature of inflammation, other causes of eosinophilia need to be ruled out prior to assigning EGID as a diagnosis [18] ( Table 1) .
EoE is characterized by symptoms related to esophageal dysfunction; in the young child, symptoms include vomiting, abdominal pain, and feeding problems, whereas in older children and adults, dysphagia and food impactions [19] predominate [20, 21 ] . Symptoms attributed to gastroesophageal reflux disease (GERD) that are recalcitrant to medical/surgical management of GERD can be, but are not always, presenting features of EoE [22] . Epidemiological data report an overall incidence of EoE as 1-5 in 10 000 with male sex predominance. Case series are increasing from previously underreported regions such as some parts of Europe, the Middle East, and Asia [4, [23] [24] [25] . A family history of esophageal dilations is common. As the incidence grows and phenotypic descriptions expand, histological patterns are becoming more important. Eosinophil numbers remain the histological diagnostic feature but other components such as extracellular eosinophil granule deposition and other measures of inflammation (basal cell hyperplasia, rete peg elongation, dilated intercellular spaces, mastophilia, T cells, fibrosis, etc.) are also increased in the esophageal mucosa [26 ,27-30,31 ,32] . With respect to granule deposition, several studies have addressed this issue and suggest that the presence of extracellular granules occurs more often in the mucosa affected by EoE compared to GERD [33] [34] [35] [36] (Fig. 1) . A recently updated consensus report summarizes the most recent experiences and literature focusing on the clinical features and treatment of EoE [21 ] . See Table 2 for a summary of the changes from the original report [20] . 
Figure 1 Eosinophils in eosinophilic esophagitis
Hematoxylin and eosin and eosinophil peroxidase staining of the esophageal tissue from a patient with eosinophilic esophagitis (EoE). EPX antibody (Clone: MM25-82.2) was used to stain a section from a patient with EoE. EPX (black dots) staining is evident in the squamous epithelia that is not easily evident in the hematoxylin and eosin stained tissue. [41] [42] [43] [44] . Clinical experiences suggest that the more distal the eosinophilia from the esophagus, the less likely that a dietary allergen will be found to resolve symptoms and histopathological findings. In some circumstances, mast cell stabilizers and leukotriene antagonists may offer clinical benefit but no clinical trials have been performed. Novel biological agents such as anti-IL-5 antibody are on the horizon as potential new therapeutic agents for EoE and potentially other EGIDs.
Pathogenetic mechanisms: do not assume the obvious -could eosinophils have a homeostatic role in the gastrointestinal tract of healthy individuals?
The overwhelming focus of investigations linking pathology and symptoms in EGIDs often views the eosinophil as an interloper, a marauding proinflammatory leukocyte whose recruitment is a prelude to tissue destruction. However, this portrayal of the eosinophil belies the reality that, with the exception of the esophagus, the eosinophil is a prominent resident leukocyte of the gastrointestinal tract as discussed above and by others [45, 46] . The presence of these resident eosinophils in otherwise healthy individuals leads to a paradox: how is the presence of eosinophils necessary to maintain homeostasis at baseline and yet their presence is a hallmark and defining feature of EGIDs? We suggest that a better understanding of this paradox and, in turn, its resolution will provide a unique perspective to understand the role of eosinophils in EGIDs. There are three potential explanations for this paradox. First, resident eosinophils serve no role in the gastrointestinal tract in healthy individuals. As surprising as this statement may be, it had been one of the more common explanations offered for the presence of gastrointestinal eosinophils. In this hypothesis, the toxic character of eosinophils necessitated an extraordinary mechanism to remove these cells from the body. The gastrointestinal tract offered such a mechanism by acting as a sink for peripheral eosinophils as a means to remove these cells without collateral damage. Second, the activities of resident gastrointestinal eosinophils are inherently different from the pathological activities mediated by the recruited eosinophils accumulating as part of disease. Clearly, if one assumes that resident eosinophils have a functional role in healthy individuals and a pathological role in disease, the most parsimonious explanation for this duality is that the activities mediated by these two eosinophil populations are different. Indeed, the literature abounds with suggestions that eosinophils undergo one or more events leading to an inflammatory leukocyte that is unique relative to the 'resting' eosinophils found in peripheral circulation. These suggestions took many forms. On a morphological level, it was suggested that inflammatory eosinophils were hypodense relative to their 'resting' counterparts [47, 48] . However, this vague more qualitative characterization gave way to specific molecular markers that correlated with the events described as eosinophil 'priming' or 'activation' [49] [50] [51] . As it related to the gastrointestinal tract, resting eosinophils may be sentinels whose presence was an early defensive shield to the possibility of microbial infection in a region that represented the largest environmental interface the body offers [52, 53] . Thus, low numbers of eosinophils serve as sentinels that activate and multiply in number when confronting an infection. That is, gastrointestinal eosinophils in healthy individuals were 'resting' leukocytes that were triggered in response to pathogen. In this paradigm, EGIDs represent a form of immune dysfunction mimicking the events linked with parasite infection and in doing so, inadvertently unleash the nonspecific destructive capabilities of eosinophils; the ensuing tissue damage and local inflammatory events simply being unavoidable collateral damage. The third explanation for the presence of eosinophils in both health and disease suggests that resident eosinophils and those recruited during disease have exactly the same functions. The key for this hypothesis is that changing events in the gastrointestinal microenvironment elicit increases in the number, but not the activities, of eosinophils. The dynamic changes occurring in disease simply require more of the same eosinophilmediated activities to maintain homeostasis. The 518 Immunology PPIs may have anti-inflammatory or barrier-healing properties that contribute to resolution of esophageal eosinophilia EoE, eosinophilic esophagitis; HPF, high power field. Modified from [21 ] .
fundamental issue in the case of the gastrointestinal tract is how eosinophils contribute to gut homeostasis and why are greater numbers of them required in disease states. Specifically, are these cells part of the immunomodulation of the mucosal microenvironment or are they agents of remodeling/repair linked to the continual and dynamic turnover of the gut epithelium? The point of interest here is that these proposed eosinophil activities are qualitatively the same in health and disease [54] . In this perspective, the immunoregulatory demands on the gut mucosal interface are enormous given the ubiquitous bacterial burden in this compartment. As such, the loss of epithelial barrier functions associated with many gastrointestinal diseases becomes a driver of eosinophil accumulation in these patients. Finally, epithelial cell turnover and stem cell activities require an ongoing commitment to remodeling/repair even in otherwise healthy individuals. Again, the damage linked with disease pathology would simply necessitate an increase in eosinophil numbers and, in turn, eosinophil-mediated remodeling/ repair activities.
Eosinophilic esophagitis: increasing evidence for Th2 responses
Clinical practice is shedding light on the identification of different subtypes of patients with EoE, whereas translational and basic studies continue to provide more insights into the key elements defining the pathogenesis of this disease [55] . Together, these experiences and studies will provide direction toward novel therapeutic targets.
Genes
In addition to eotaxin-3, a number of other genes have now been associated with EoE, including transforming growth factor (TGF)-b-1, filaggrin, and thymic stromal lymphopoietin (TSLP) [56 ,57,58 ,59] . TSLP is an epithelial derived IL-7-like cytokine that can activate a number of immune cells, in particular dendritic and mast cells. Filaggrin is a barrier gene that has been linked to barrier dysfunction in atopic dermatitis.
Epithelial immunomilieu: a diverse microenvironment is under definition
Eosinophils are the most readily recognized leukocyte associated with EoE, but they are not the only cells present in the affected esophageal mucosal surface. Studies measuring FoxP3 staining and human leukocyte antigen-DR expression in children and adult mucosae have been met with variable results [60] [61] [62] . A cell line of esophageal epithelia has been shown to possess the machinery to present antigen posing an interesting new paradigm for the pathogenesis of EoE [63] . Esophageal mucosae of adults and children with EoE were shown to have significantly increased mast cells [26 ,31 ,64] . Fibroblast growth factor expression in EoE tissues from children was associated with peripheral blood mononuclear cell expression of pro-apoptotic factors Fas and caspase-8 suggesting prolongation of eosinophil lifespan [65] . Although these studies continue to define the microenvironment associated with EoE, all patients may not have the same immunomilieu; future studies identifying the exact immunological features of specific clinical phenotypes may be difficult to measure but will be important to determine.
Mouse models and ex-vivo systems using human tissues support the concept that EoE is a Th2-driven disease. A recent comparative analysis of five EoE patients with five normal patients revealed more than four-fold upregulation of 19 cytokine genes (including eotaxin-3, IL-13, IL-5, IL-5r, CXCL1) and downregulation of two genes [breast and kidney-expressed chemokine (BRAK) and IL-1F6] [66] . Of the upregulated genes, there was a significant correlation with disease activity. Other studies suggest EoE may be an IL-13 and/or IL-15 epithelial driven disease [67, 68] . For instance, IL-15r null mice were protected from eosinophilia [67] . Ex-vivo analysis of esophageal epithelia revealed expression of both IL-15 and IL-15r, a finding that correlated with mucosal eosinophilia.
Chronic inflammation: mechanistic insights and functional impaction
The major clinical concern regarding chronic esophageal eosinophilia has been the impact of eosinophils and their products on remodeling, fibrosis, and stricture formation. This later potential impact has driven much of the vigor and attention to treatments. Clinical correlates identify increased fibrosis in the esophageal mucosa of children and adults with EoE, but criteria to measure this feature remain variable. To address this concern, a series of works identified a prominent role for TGF-b in remodeling events in EoE and demonstrate a role for mast cells and TGF-b in esophageal smooth muscle contraction [26 ] . Methodologies to measure esophageal function are lacking. Recently, a study using the novel tool the endoflip, demonstrated reduced esophageal compliance in adults with EoE, a finding supportive of fibrosis or possibly increased esophageal tone [69] . Together, these findings support the concept that eosinophilia can contribute to esophageal dysmotility, but who, how, and when these issues develop is unknown.
Eosinophilic gastritis and colitis: mechanistic elements
Although studies of the esophagus and other organ systems such as the lung have identified potential roles for eosinophils in stimulating tissue remodeling, inducing epithelial barrier dysfunction and smooth muscle contraction, few studies have addressed these issues in the rest of the gastrointestinal tract.
Previous studies focusing on the mechanisms of eosinophil recruitment identified the role of eotaxin-1 in the chemotaxis of eosinophils to the gastrointestinal mucosa. Utilizing bone marrow chimeras, a recent study demonstrated the impact of Ly6C high CCR2þ monocyte/macrophage CCL11 on eosinophil recruitment in dextran sodium sulfate colitis [70 ] . A few studies have examined the impact of eosinophils on colonic function utilizing models of inflammatory bowel diseases. For example, oxazolone-treated mice develop a Th2-type cytokine and colonic eosinophilia profile similar to ulcerative colitis [71] . Use of this mouse model in eosinophil granule protein null animals has demonstrated the pathological impact of major basic protein (MBP) and eosinophil peroxidase (EPO) in colitis. Two studies showed that mice congenitally deficient in eosinophil development are protected from experimental colitis [71, 72] . A spontaneous mouse model of ileitis, the SAMP1 mice, develops eosinophilia and ileal remodeling [73] . Mice treated with anti-CCR3 antibody responded with diminished eosinophilia, decreased goblet cell hyperplasia, and decreased smooth muscle mass [74] . Together, these studies support a role for eosinophils in lower gastrointestinal remodeling and dysfunction.
Because of the potential role of allergic T-cell responses, IgE-mediated reactions have been considered as one of the mechanisms contributing to EGIDs. As such, anti-IgE therapy was used to treat eight patients with EGIDs. A 16-week trial of omalizumab resulted in no impact on T-cell proliferation, antigen dose responses, precursor frequency, or cytokine expression [75] . These findings do not support a direct role for IgE in EGIDs.
Eosinophils express a number of cytokine receptors, including those associated with remodeling and fibrosis: IL-13, TGF-b, and tumor necrosis factor (TNF). Eosinophils can respond differently to their microenviron-ment, inducing expression of either Th1 or Th2-associated chemokines and, thus, may play a role in orchestration of the immune milieu in EGIDs.
Numerous histological studies have described increased eosinophil presence in intestinal mucosal biopsies. In addition, granule proteins have been detected in colonic perfusion fluids and stool samples from patients with intestinal inflammation. Thus, eosinophils are present and secrete their granule contents. However, the role and function of the eosinophil in intestinal inflammation remains unclear. Eosinophils while containing an armamentarium of molecules shown to elicit dysfunctional effects in other organs, particularly the lung, have not yet been examined in detail in the intestines. In this regard, immunohistochemical assessment of human tissues affected by inflammatory bowel diseases demonstrates increased staining for EPX suggesting a potential role for eosinophil activation in these diseases (Fig. 2) . Further basic and translational investigations are necessary in this area to provide insights into eosinophil response to tissue microenvironments, mechanisms contributing to pathology and descriptions of patient/disease phenotypes, and may lead to novel targeted therapeutic options for these EGIDs.
Conclusion
In summary, eosinophils continue to be enigmatic cells that likely serve a role in health and disease. Eosinophil enumeration continues to be the gold standard for fulfilling the histological diagnostic parameter, but future studies will characterize other meaningful criteria that may not only include histology, but also molecular parameters. Functional studies of EGIDs are lacking and much needed to understand the physiological and pathophysiological roles of eosinophils in the gastrointestinal tract. Because of the overall rarity and mechanistic overlaps of EGIDs, collaborative, multidisciplinary studies will provide the most rapid and meaningful discoveries. 
